Loading…
Employees: 566
Size Medtide (3880.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $358M, the 840th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$19.82 on 6 Nov 2026.
Performance Over six months the shares fell 9.3%, against -32.7% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 14.0% over the last twelve months (peer median -8.8%); the operating margin is 35.9% (peer median -621.1%).
Valuation It trades at 11.4× forward earnings against a peer median of 18.7× (2nd cheapest of 4).
Capital Return on invested capital runs 19.1 points above its cost of capital (5.3% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$614M | HK$618M | HK$479M | HK$372M | HK$408M |
| Revenue growth | — | +29% | +29% | -9% | — |
| Gross profit | HK$381M | HK$392M | HK$271M | HK$199M | HK$234M |
| EBITDA | HK$254M | HK$280M | HK$173M | HK$126M | HK$162M |
| Net income | HK$187M | HK$236M | HK$64.2M | HK$54.0M | HK$62.8M |
| Free cash flow | -HK$74.1M | HK$149M | HK$107M | HK$36.6M | HK$48.6M |
| Capital expenditure | HK$216M | HK$141M | HK$24.3M | HK$61.5M | HK$107M |
| Total debt | n/a | HK$34.2M | HK$36.7M | HK$332M | HK$365M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3880.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.6% | -17.2% | 6th highest of 20 |
| 6-month return | -9.3% | -32.7% | 5th highest of 19 |
| Distance from 52-week high | -38.0% | -53.3% | 5th highest of 20 |
| Revenue growth (TTM) | +14.0% | -8.8% | 5th highest of 16 |
| Operating margin | 35.9% | -621.1% | highest of 15 |
| Forward P/E | 11.4× | 18.7× | 2nd cheapest of 4 |
| ROIC minus cost of capital | +19.1 pp | -76.1 pp | 2nd highest of 12 |
| EV / EBITDA | 6.6× | 20.1× | 2nd cheapest of 4 |
| Net debt / EBITDA | -4.5× | -3.5× | least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 11.4× | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | n/a | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 9.5× | 5.6% | +19.1% |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | n/a | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | n/a | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | n/a | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | n/a | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | n/a | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 18.7× | n/a | n/a |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | n/a | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | n/a | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | n/a | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | n/a | n/a | n/a |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | n/a | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $330M | -32% | -100% | n/a | n/a | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | 26.1× | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | n/a | 2.0% | +725.2% |